Company / Shareholders' Equity
Twist Bioscience Corp Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$473.0M
FY2025
5-year range
$472.7M / $789.4M
FY2021-FY2025
Trend
+0.1%
vs FY2024
Sector context
#101 of 215
Health Care
What the data says
At $473M, Twist Bioscience Corp's shareholders' equity ranks #101 of 215 in the Health Care sector. Shareholders' Equity returned to growth in FY2025 after 2 years of decline, reaching $473M.
Based on SEC 10-K filings.
$473M in FY2025 with a 5-year CAGR of +7.1%.
Declined from $623M to $473M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -15.7%
- 5-Year CAGR
- +7.1%
- 10-Year CAGR
- -
Sector benchmark
#101 of 215 in Health CareTop 47% of 215This company $473.0M Sector average $2.6B
▼
-81.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +7.1%, indicating consistent growth.
- In FY2025, shareholders' equity increased 0.1% year-over-year.
- Ranks #101 out of 215 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $473.0M | +0.1% |
| FY2024 | $472.7M | -24.2% |
| FY2023 | $623.4M | -21.0% |
| FY2022 | $789.4M | +35.9% |
| FY2021 | $580.8M | +72.7% |
| FY2020 | $336.3M | +121.1% |
| FY2019 | $152.1M | +175.5% |
| FY2018 | -$201.4M | -51.0% |
| FY2017 | -$133.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026